ASX Release

14 October 2024

CLINICAL ADVISORY BOARD ESTABLISHED IN PREPARATION FOR FDA IND APPLICATION

MELBOURNE, AUSTRALIA 14 October 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce the appointment of three key opinion leaders and clinical oncologists to establish its Clinical Advisory Board (CAB).

The CAB will provide expert clinical insight and strategic advice focusing on CD19-positive haematological malignancies (blood cancers), as the Company looks to file its IND and commence its first-in-human phase 1 clinical trial. The members that will be appointed to Arovella's CAB are:

- **Dr Salvatore Fiorenza**, Deputy Director and Cell Therapy Lead at Epworth Healthcare;
- **Professor Sattva Neelapu**, Professor and Deputy Chair at the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center; and
- **Dr Debora Barton**, a Medical Oncologist who is also currently a Non-executive Director at Arovella.

Each member has been carefully selected, due to their experience working with cell therapies in early-stage clinical trials.

Dr Salvatore (Sam) Fiorenza

Dr Salvatore (Sam) Fiorenza (MBBS, PhD, BSc (Hons), MPH, FRACP, FRCPA) is a consultant haematologist, deputy director and medical lead of cell therapy at Epworth Healthcare in Melbourne and a senior postdoctoral research scientist at the University of Sydney with Prof Cameron Turtle. Dr Fiorenza holds a PhD in cellular immunotherapy and a Master of Public Health and completed a postdoctoral research fellowship funded by The Haematology Society of Australia and New Zealand in CAR-T at the Fred Hutchinson Cancer Center in Seattle, USA.

Dr Fiorenza is recognised for his expertise in the development and application of CAR-T cell therapies and his clinical and research efforts are focused on advancing treatments for patients with hematologic malignancies, particularly those with lymphomas and other blood cancers.

Dr Fiorenza has played a significant role in the implementation of CAR-T therapies in Australia, participating in both clinical trials and treatment protocols aimed at improving outcomes for patients with relapsed or refractory blood cancers. Through his leadership, Epworth Healthcare has become a leading centre for CAR-T therapy, and his work has contributed to the growing body of evidence supporting CAR-T as a transformative treatment for patients with few other therapeutic options.

Dr Fiorenza will also Chair the CAB.

Professor Sattva Neelapu

Dr Sattva Neelapu, MD, is a Professor and Deputy Chair in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. He is internationally recognised for his pioneering contributions to the development of immunotherapies for blood cancers, particularly in CAR-T therapies. His research and clinical practice focus on lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and other hematologic malignancies.

Dr Neelapu has been instrumental in leading numerous clinical trials, notably those that paved the way for the FDA approval of CAR-T cell therapies, such as axicabtagene ciloleucel (Yescarta). This therapy revolutionised the treatment options for patients with relapsed or refractory large B-cell lymphoma, offering a potential cure for patients who had previously exhausted other treatment avenues. Dr Neelapu has also been a clinical advisor and investigator for several allogeneic cell therapy products in development.

Dr Neelapu has authored over 300 peer-reviewed articles in prestigious medical journals such as *The New England Journal of Medicine*, *Nature Medicine*, and *The Lancet Oncology*. His work is widely cited in the field of immunotherapy, and he has delivered numerous keynote presentations at international oncology conferences. His achievements have earned him multiple awards and recognition within the oncology community, and he was recently elected as a fellow of the American Association for the Advancement of Science.

Dr Neelapu is recognised as a leader in immuno-oncology, and he continues to drive advancements in cancer treatment through his research and clinical leadership.

Dr Debora Barton

Dr Debora Barton, MD, is a highly regarded oncologist with a significant focus on cell therapies. Throughout her career, Dr Barton has been Chief Medical Officer of several biotechnology companies developing novel cell therapies and has extensive experience designing and running clinical trials from first-in-human phase 1 through to phase 3. She has worked to optimise patient outcomes and minimise adverse effects, ensuring that this cutting-edge treatment can be safely integrated into broader cancer care.

Dr Barton's involvement in immunotherapy and haematologic oncology is highly recognised within the oncology community. Her work continues to impact the evolving landscape of cancer treatments, particularly through her focus on innovative cellular therapies like Arovella's CAR-iNKT cell platform. Dr Barton is also a Non-executive Director at Arovella.

Arovella's Chief Executive Officer and Managing Director, Dr Michael Baker, commented, "We are thrilled to have such high-calibre clinical oncologists willing to join our Clinical Advisory Board and help us on our journey to advance our novel cell therapy platform into clinic. We look forward to working with them to guide our programs and help patients in need of new and effective treatment options."

Release authorised by the Chief Executive Officer and Managing Director of Arovella Therapeutics Limited, Dr Michael Baker.

CONTACT

Investors
Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Ltd
Tel +61 (0) 403 468 187
investor@arovella.com

Media
Matthew Wright
NWR Communications
Tel +61 451 896 420
matt@nwrcommunications.com.au

NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

Glossary: iNKT cell – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be

placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.